OOIR: Observatory of International Research

Papers

(The H4-Index of Influenza and Other Respiratory Viruses is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Issue Information	209
	77
	76
Predicting virologically confirmed influenza using school absences in Allegheny County, Pennsylvania, USA during the 2007‐2015 influenza seasons	70
Effectiveness of the XBB.1.5 COVID‐19 Vaccines Against SARS‐CoV‐2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 t	66
Antibiotic prescription for outpatients with influenza and subsequent hospitalisation: A cohort study using insurance data	66
Low prevalence of seasonal influenza viruses in Hong Kong, 2022	55
EMARIS Conference 2023: Convergence of science, policy, and practice on acute respiratory infections in post COVID‐19 Eastern Mediterranean Region	53
Infection‐induced seroconversion and seroprevalence of SARS‐CoV‐2 among a cohort of children and youth in Montreal, Canada	49
Issue Information	45
Meeting Report: Controlled Human Influenza Virus Infection Model Studies: Current Status and Future Directions for Innovation	42
Avian Influenza Virus (H5N1) Was Not Detected Among Dairy Cattle and Farm Workers in Pakistan	36
SARS‐CoV‐2 infection rate in Antananarivo frontline health care workers, Madagascar	36
A comparative immune response to COVID‐19 vaccination between children and adults	35
Comparative complete scheme and booster effectiveness of COVID‐19 vaccines in preventing SARS‐CoV‐2 infections with SARS‐CoV‐2 Omicron (BA.1) and Delta (B.1.617.2) variants: A case–case study based on	35
A novel household‐based patient outreach pilot program to boost late‐season influenza vaccination rates during the COVID‐19 pandemic	35
Lower cognitive scores among toddlers in birth cohorts with acute respiratory illnesses, fevers, and laboratory‐confirmed influenza	34
Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study	34
No evidence for HPAI H5N1 2.3.4.4b incursion into Australia in 2022	34
Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post‐vaccination but persist for at least 6 months	33
Risk factors and medical resource utilization in US adults hospitalized with influenza or respiratory syncytial virus in the Hospitalized Acute Respiratory Tract Infection study	31
Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial	29
Cross‐Reactive Antibody Responses to Coronaviruses Elicited by SARS‐CoV‐2 Infection or Vaccination	29
Next‐Generation Sequencing for Characterizing Respiratory Tract Virome and Improving Detection of Viral Pathogens in Children With Pneumonia	28
Drug use and severe outcomes among adults hospitalized with influenza, 2016–2019	27

Severe acute respiratory syndrome coronavirus 2 can be detected in exhaled aerosol sampled during a few minutes of breathing or coughing